SynthesisEndocrine2015
Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.
Synthesis in Endocrine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.PloS one · 2018Pooled it
- Acute pancreatitis following semaglutide therapy: a case report.Annals of medicine and surgery (2012) · 2026Article
- Acute pancreatitis as a complication of epstein-barr virus infection: A case report and narrative review.IDCases · 2026Article
- Glucose-lowering therapy in diabetes of the exocrine pancreas: a real-world evidence analysis in a tertiary hospital in the timeframe 2018-2022.Therapeutic advances in endocrinology and metabolism · 2026Article
- Dose-dependent pancreatitis risk associated with GLP-1 agonists.Journal of diabetes and metabolic disorders · 2025Article
- The potential adverse effects of hypodermic glucagon-like peptide -1 receptor agonist on patients with type 2 diabetes: A population-based study.Journal of diabetes · 2024Article
- Acute Pancreatitis Likely Due to Semaglutide.Cureus · 2024Article
- Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- Acute Pancreatitis in a Patient Taking Semaglutide.Cureus · 2023Article
- Article
- Diabetes following acute pancreatitis.The lancet. Gastroenterology & hepatology · 2021Review
- Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia.Clinical medicine insights. Endocrinology and diabetes · 2021Review
- Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.Journal of clinical pharmacy and therapeutics · 2020Review
- Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.Advances in therapy · 2019Review
- Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.Diabetes, obesity & metabolism · 2019Article
- Comparison of biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users: a cross-sectional study from Anuradhapura, Sri Lanka.Journal of health, population, and nutrition · 2019Article
- DPP-4 Inhibition and the Path to Clinical Proof.Frontiers in endocrinology · 2019Review
- Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Systematic Review and Meta-analysis in Patients with Type 2 Diabetes Mellitus.Iranian journal of pharmaceutical research : IJPR · 2019Article
- Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2018Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concerns raised by several animal studies, case reports, and pharmacovigilance warnings over incretin-based therapy potentially exposing type two diabetes patients to an elevated risk of pancreatitis have cast a shadow on the overall safety of this class of drugs. This systematic review evaluates the data from observational studies that compared treatment with or without incretins and the risk of pancreatitis. We searched PubMed for publications with the key terms incretins or GLP-1 receptor agonists or DPP-4 inhibitors or sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin or exenatide or liraglutide AND pancreatitis in the title or abstract. Studies were evaluated against the following criteria: design (either cohort or case-control); outcome definition (incidence of pancreatitis); exposure definition (new or current or past incretins users); and comparison between patients receiving incretins or not for type 2 diabetes. Two authors independently selected the studies and extracted the data. Six studies meeting the inclusion criteria were reviewed. No difference was found in the overall risk of pancreatitis between incretin users and non-users (odds ratio 1.08; 95 % CI [0.84-1.40]). A risk increase lower than 35 % cannot be excluded according to the power calculation. This systematic review and meta-analysis suggests that type 2 diabetes patients receiving incretin-based therapy are not exposed to an elevated risk of pancreatitis. Limitations of this analysis are the low prevalence of incretin users and the lack of a clear distinction by the studies between therapy with DPP-4 inhibitors or with GLP-1 receptor agonists.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.